Li Sheng Zhao Spends CN¥436k On Kingworld Medicines Group Stock
Li Sheng Zhao Spends CN¥436k On Kingworld Medicines Group Stock
Even if it's not a huge purchase, we think it was good to see that Li Sheng Zhao, the Co-Founder of Kingworld Medicines Group Limited (HKG:1110) recently shelled out HK$436k to buy stock, at HK$0.44 per share. Nevertheless, it only increased their shareholding by a minuscule percentage, and it wasn't a massive purchase by absolute value, either.
即使这不是一笔巨额交易,我们认为金活医药集团有限公司(HKG:1110)的联合创始人李胜赵最近以每股0.44港元的价格斥资43.6万港元购买股票是件好事。然而,这仅仅增加了他们的股东持股比例很小,绝对价值也不算巨大。
Kingworld Medicines Group Insider Transactions Over The Last Year
金活医药集团一年内的内部交易情况
Notably, that recent purchase by Li Sheng Zhao is the biggest insider purchase of Kingworld Medicines Group shares that we've seen in the last year. That means that an insider was happy to buy shares at above the current price of HK$0.41. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. The only individual insider to buy over the last year was Li Sheng Zhao.
值得注意的是,李胜赵最近的这次购买是金活医药集团股份在过去一年内最大的内部人士购买。这意味着内部人士愿意以上市价0.41港元以上的价格购买股票。他们很可能对此次交易感到后悔,但更可能是看好这家公司。对我们来说,考虑内部人士购买股票的价格非常重要。一般来说,当内部人士以高于当前股价购买股票时,我们会关注,因为这表明他们认为这些股票值得购买,即使价格较高。过去一年中唯一一位个人内部人士的购买者是李胜赵。
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
您可以在下面的图表中查看过去一年(由公司和个人)的内部交易。通过单击下面的图表,您可以查看每个内部交易的详细信息!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
还有很多其他的公司,公司的内部人士正在购买股票。你可能不想错过这个免费的小市值公司的低估列表。
Does Kingworld Medicines Group Boast High Insider Ownership?
金活医药集团是否拥有高内部股权所有权?
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Kingworld Medicines Group insiders own about HK$168m worth of shares (which is 70% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
对于普通股东而言,值得检查公司内部人员持有多少股份。我认为,如果内部人员拥有公司内一定数量的股份,这是一个好迹象。金活医药集团的内部人员拥有价值约为HK$16800万的股份(约占公司股份的70%)。我喜欢看到这种内部股权所有权水平,因为这增加了管理层考虑股东最佳利益的机会。
So What Does This Data Suggest About Kingworld Medicines Group Insiders?
那么这些数据对金活医药集团的内部人员意味着什么?
It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Kingworld Medicines Group. Nice! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example - Kingworld Medicines Group has 2 warning signs we think you should be aware of.
最近的内部人员购买情况确实令人振奋。对过去一年交易的分析也增强了我们的信心。一旦考虑到高内部人员持股,看起来内部人员对金活医药集团持乐观态度。不错!因此,了解内部人员在购买或出售方面的行为是很有帮助的,同时了解某家公司面临的风险也很有帮助。举例来说——金活医药集团有2个警示迹象,我们认为您应该意识到。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果您想查看另一家公司的信息-一家潜在具有优秀财务状况的公司-请不要错过这个带有高股权回报率和低债务的有趣公司免费列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。